Skip to main content
  • 2193 Accesses

Summary

These examples were meant to illustrate the process that modelers go through in developing models: data clean-up, model building, model evaluation, how to use a model once one is developed, etc. Some models can be developed quite simply. Others are quite complex. Are these the best models? Probably not. But the models that were developed were adequate to reach the desired goal. It is important before a project is tackled to identify the goal and see what is the quickest way to get there. It does no one any good for a modeler who presents too complex a model when a simpler one can be used instead.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Recommended Reading

  • De Alwis, D.P., Aarons, L., and Palmer, J.L. Population pharmacokinetics of ondansetron: A covariate analysis. British Journal of Clinical Pharmacology 1998; 46: 117–125.

    Article  PubMed  Google Scholar 

  • Gieschke, R., Burger, H.-U., Reigner, B., Blesch, K.S., and Steimer, J.-L. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. British Journal of Clinical Pharmacology 2003; 55: 252–263.

    Article  CAS  PubMed  Google Scholar 

  • Gisleskog, P.O., Hermann, D., Hammarlund-Adenaes, M., and Karlsson, M.O. Validation of a population pharmacokinetic/pharmacodynamic model for 5a-reductase inhibitors. European Journal of Pharmaceutical Sciences 1999; 8: 291–299.

    Article  Google Scholar 

  • Kerbusch, T., Wahlby, U., Milligan, P.A., and Karlsson, M.O. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. British Journal of Clinical Pharmacology 2003; 56: 639–652.

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

(2006). Nonlinear Mixed Effects Models: Case Studies. In: Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Springer, Boston, MA. https://doi.org/10.1007/0-387-27199-6_9

Download citation

Publish with us

Policies and ethics